Bob Bradway
The Steward
Legacy, values and the long now, leadership as care and continuity.
Bob Bradway presents as a classic Steward, someone who frames every strategic decision through the lens of custodianship over a mission larger than commercial ambition. Throughout this interview, Bradway consistently anchors Amgen's competitive intensity, its genetic research in Iceland, its AI investments, and its pricing discipline back to patient welfare as an organizing principle.
“And sometimes that failure occurs 10, 12, 15 years after we've committed and been investing in a project. And that can be frustrating as heck. The beautiful thing about our field, however, is that we learn. We learn from failure.”
“And I would note, Simon, there are really two of us left from that original wave of biotechnology companies that crept up in the landscape in the United States. Only two of us left as independent thriving biotechnology companies. So our evolution was one of a couple of very successful breakthrough medicines.”
“So I've benefited tremendously from having people that have been through some of the things that I'm going through and can help me think through challenges and look around corners. So really grateful to them for that. At the other end, you are talking and your colleagues are talking to young people, students.”
“All right. If you grant me a sunny day, Simon, I might say I'd go up to Northern Scotland, flying to Inverness and rent a car and drive out to Royal Dornick because on a sunny day, there's a few more wonderful experiences than that. Who would I play on that course with? Well, Simon, I would hope you are available on that sunny day.”
Money Maze Podcast: “Biotechnology and Healthcare: A New Dawn? With Bob Bradway, CEO of Amgen”
LISTEN AT THE SOURCE ↗THE RECORD IS CHECKABLE